Ceryvyn Therapeutics (ASX:CYV) Issuance of Debt: A$0.00 Mil (TTM As of Jun. 2025)


What is Ceryvyn Therapeutics Issuance of Debt?

Ceryvyn Therapeutics ASX:CYV -7.69% Issuance of Debt is A$0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's Issuance of Debt for the six months ended in Jun. 2025 was A$0.00 Mil.

Ceryvyn Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.00 Mil.

Ceryvyn Therapeutics Issuance of Debt Related Terms

Ceryvyn Therapeutics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Issuance of Debt Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ceryvyn Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of A$0.00 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Issuance of Debt of A$0.00 Mil as of Jun. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Issuance of Debt too high?
Ceryvyn Therapeutics' current Issuance of Debt is A$0.00 Mil.
How does Ceryvyn Therapeutics' Issuance of Debt compare to VRTX and REGN?
Ceryvyn Therapeutics' Issuance of Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Issuance of Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Issuance of Debt of A$0.00 Mil. The current Issuance of Debt is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Issuance of Debt is A$0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.